Nicolas Poirier
Chief Executive Officer bei OSE IMMUNOTHERAPEUTICS
Vermögen: 1 Mio $ am 31.03.2024
Profil
Nicolas Poirier is currently the Chief Executive Officer & Director at OSE Immunotherapeutics SA since 2022.
Previously, he worked as a Project Manager at Effimune SA. Dr. Poirier has a graduate degree from the University of Nantes and Louis Pasteur University, and an undergraduate degree from the Centre d'Etudes Supérieures de Techniques Industrielles.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 31.12.2022 | 192 802 ( 0,89% ) | 1 Mio $ | 31.03.2024 |
Aktive Positionen von Nicolas Poirier
| Unternehmen | Position | Beginn |
|---|---|---|
| OSE IMMUNOTHERAPEUTICS | Chief Executive Officer | 07.10.2022 |
Ehemalige bekannte Positionen von Nicolas Poirier
| Unternehmen | Position | Ende |
|---|---|---|
Effimune SA
 Effimune SA BiotechnologyHealth Technology Effimune SA engages in the research and development of drugs for transplantation and immune-mediated diseases. It covers the identification of novel therapeutic targets, the development of therapeutics, pilot manufacturing, set-up of animal models, pre-clinical and early clinical development. The company was founded by Maryvonne Hiance, Bernard Vanhove and Sophie Brouard in 2007 and is headquartered in Nantes, France. | Corporate Officer/Principal | - |
Ausbildung von Nicolas Poirier
| University of Nantes | Graduate Degree |
| Centre d'Etudes Supérieures de Techniques Industrielles | Undergraduate Degree |
| Louis Pasteur University | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| OSE IMMUNOTHERAPEUTICS | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Effimune SA
Effimune SA BiotechnologyHealth Technology Effimune SA engages in the research and development of drugs for transplantation and immune-mediated diseases. It covers the identification of novel therapeutic targets, the development of therapeutics, pilot manufacturing, set-up of animal models, pre-clinical and early clinical development. The company was founded by Maryvonne Hiance, Bernard Vanhove and Sophie Brouard in 2007 and is headquartered in Nantes, France. | Health Technology |
